Skip to main content

SONATA

Category: AI in Healthcare

Doctor-led preventive healthcare membership combining whole-genome sequencing, biomarker testing, and clinical AI with ongoing physician-led care. SONATA was founded in 2025. The company is led by Sagan Schultz, MD, MBA. Based in New York, United States. Team size: 11-50. Total funding raised: $7M. Latest round: Seed. Key investors include Lux Capital, BoxGroup, Sunflower Capital, Angel investors including founders of Ramp and Linear.

Founded
2025
Headquarters
New York, United States
Team size
11-50
Total funding
$7M

Value proposition

SONATA closes the gap between health data and actionable care by pairing deep biological testing (whole-genome sequencing, 140+ blood biomarkers, DNA methylation analysis) with board-certified physicians and an in-house clinical AI platform, all in a single annual membership.

Products and solutions

Annual preventive healthcare membership ($2,500 founding price) including: whole-genome sequencing, 140+ blood biomarkers, DNA methylation (biological age) analysis, in-home blood draws, wearable data integration, unlimited physician-led care team visits, and in-house clinical AI platform for pattern detection across genetics, labs, medical history, and daily life.

Unique value

Only preventive healthcare membership that combines clinical-grade whole-genome sequencing, DNA methylation aging analysis, 140+ biomarkers, and in-house clinical AI — all anchored by ongoing board-certified physician relationships, not one-time reports. Priced at $2,500/year vs. $25K+ for traditional concierge medicine.

Target customer

Health-conscious individuals in their 30s-40s who are already spending on wearables, testing, and supplements but lack coordinated clinical guidance; priced at $2,500/year founding membership (vs. $25K+ for traditional concierge medicine).

Industries served

Preventive healthcare, longevity medicine, concierge medicine, women's health (cycle-aware hormone testing)

Technology advantage

In-house clinical AI platform that connects patterns across genetics, labs, medical history, and daily life; clinical-grade whole-genome sequencing pipeline; DNA methylation (biological age) measurement using same methods as aging research; physician-led model where AI augments (not replaces) clinical decision-making.

How they differentiate

Unlike data-only testing services (InsideTracker, Function Health) that provide reports without ongoing clinical relationships, and unlike traditional concierge medicine priced at $25K+/year, SONATA combines clinical-grade whole-genome sequencing, DNA methylation analysis, and in-house AI with unlimited physician-led care at $2,500/year. Clinical decisions remain physician-led, not algorithm-driven.

Main competitors

Function Health, Mito Health, InsideTracker, Parsley Health

Major milestones

Founded in 2025 by Sagan Schultz and David Deng, Raised $7M seed round led by Lux Capital in July 2026, Launched from stealth in July 2026 with availability in New York, San Francisco, and Los Angeles

Market positioning

Premium preventive healthcare positioned between data-only wellness testing services and high-end concierge medicine ($25K+). Targets the "unconverted" market of health-conscious consumers already spending on fragmented health solutions.

Geographic focus

US (launched in New York, San Francisco, and Los Angeles)

About Sagan Schultz, MD, MBA

First product manager at Linear; former McKinsey healthcare consultant; MD/MBA from NYU Stern School of Business

Latest news about SONATA

More AI in Healthcare companies

Official website: